×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
REGN – regeneron pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
REGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/17
08:48 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $170.00 to $150.00. They now have a "hold" rating on the stock.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $170.00 to $150.00. They now have a "hold" rating on the stock.
4/17
08:14 am
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Bank of America Co. from $575.00 to $547.00. They now have an "underperform" rating on the stock.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Bank of America Co. from $575.00 to $547.00. They now have an "underperform" rating on the stock.
4/17
07:37 am
regn
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications [Yahoo! Finance]
Low
Report
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications [Yahoo! Finance]
4/17
07:00 am
regn
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications
Low
Report
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications
4/15
08:25 am
regn
Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S. [Yahoo! Finance]
Low
Report
Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S. [Yahoo! Finance]
4/14
02:22 pm
regn
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $1,019.00 to $917.00. They now have a "buy" rating on the stock.
Low
Report
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $1,019.00 to $917.00. They now have a "buy" rating on the stock.
4/14
05:40 am
regn
Reflecting On Immuno-Oncology Stocks' Q4 Earnings: Regeneron (NASDAQ:REGN) [Yahoo! Finance]
Low
Report
Reflecting On Immuno-Oncology Stocks' Q4 Earnings: Regeneron (NASDAQ:REGN) [Yahoo! Finance]
4/6
08:15 am
regn
Regeneron Pharmaceuticals (NasdaqGS:REGN) Drops 10% Over Last Week Despite Dupixent Approval in Japan [Yahoo! Finance]
Low
Report
Regeneron Pharmaceuticals (NasdaqGS:REGN) Drops 10% Over Last Week Despite Dupixent Approval in Japan [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/4/2025
06:30 am
regn
regeneron pharmaceuticals, inc.
BEAT
Report
4.6%
regeneron pharmaceuticals, inc.
2/4/2025
06:30 am
regn
regeneron pharmaceuticals, inc.
BEAT
Report
1.7%
regeneron pharmaceuticals, inc.
2/4/2025
06:30 am
regn
regeneron pharmaceuticals, inc.
BEAT
Report
2.5%
regeneron pharmaceuticals, inc.
2/4/2025
06:30 am
regn
regeneron pharmaceuticals, inc.
BEAT
Report
1.6%
regeneron pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/7
04:16 pm
regn
Form PRE 14A REGENERON PHARMACEUTICAL For: Jun 13
Low
Report
Form PRE 14A REGENERON PHARMACEUTICAL For: Jun 13
2/12
09:31 am
regn
Form SCHEDULE 13G/A REGENERON PHARMACEUTICAL Filed by: FMR LLC
Low
Report
Form SCHEDULE 13G/A REGENERON PHARMACEUTICAL Filed by: FMR LLC
2/7
04:37 pm
regn
Form 13F-HR REGENERON PHARMACEUTICAL For: Dec 31
Low
Report
Form 13F-HR REGENERON PHARMACEUTICAL For: Dec 31
2/5
09:18 am
regn
Form 10-K REGENERON PHARMACEUTICAL For: Dec 31
Low
Report
Form 10-K REGENERON PHARMACEUTICAL For: Dec 31
2/4
07:11 am
regn
Form 8-K REGENERON PHARMACEUTICAL For: Feb 04
Low
Report
Form 8-K REGENERON PHARMACEUTICAL For: Feb 04
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/17
Regeneron Announces Important Advances in Novel COVID-19 Antibody Program
7.4%
11/5 Regeneron Reports Third Quarter 2019 Financial and Operating Results 6.9%
3/3 Regeneron Announces Upcoming Investor Conference Presentations 6.9%
5/8 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its "hold" rating re-affirmed by analysts at Canaccord Genuity. They now have a $353.00 price target on the stock, down previously from $408.00. 6.5%
4/15 Form 4 REGENERON PHARMACEUTICAL For: Apr 13 Filed by: STAHL NEIL 5.5%
4/16 Form 4 REGENERON PHARMACEUTICAL For: Apr 14 Filed by: LAROSA JOSEPH J 5.3%
2/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its price target raised by analysts at Citigroup Inc from $420.00 to $540.00. They now have a "buy" rating on the stock. 5.0%
11/8 U.S. company directors compensated more than ever, but now risk backlash [Reuters] 4.9%
10/10 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 4.7%
2/28 Form 4 REGENERON PHARMACEUTICAL For: Feb 26 Filed by: SING GEORGE L 4.5%
11/5 Regeneron Reports Third Quarter 2019 Financial and Operating Results 6.9%
3/3 Regeneron Announces Upcoming Investor Conference Presentations 6.9%
5/8 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its "hold" rating re-affirmed by analysts at Canaccord Genuity. They now have a $353.00 price target on the stock, down previously from $408.00. 6.5%
4/15 Form 4 REGENERON PHARMACEUTICAL For: Apr 13 Filed by: STAHL NEIL 5.5%
4/16 Form 4 REGENERON PHARMACEUTICAL For: Apr 14 Filed by: LAROSA JOSEPH J 5.3%
2/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) had its price target raised by analysts at Citigroup Inc from $420.00 to $540.00. They now have a "buy" rating on the stock. 5.0%
11/8 U.S. company directors compensated more than ever, but now risk backlash [Reuters] 4.9%
10/10 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 4.7%
2/28 Form 4 REGENERON PHARMACEUTICAL For: Feb 26 Filed by: SING GEORGE L 4.5%
TOP News Decliners
3/19
Coronavirus Proves Drug Companies To Be Innovators [Forbes]
-10.3%
2/27 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -8.6%
3/11 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: YANCOPOULOS GEORGE -7.1%
5/7 Q1/2019 3/31/2019 EPS 4.450 ZacksConsensus 5.240 ActVsEst (0.790) - Miss -6.6%
4/20 Form 4 REGENERON PHARMACEUTICAL For: Apr 16 Filed by: LAROSA JOSEPH J -5.1%
8/14 Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol -4.1%
5/9 Form CT ORDER REGENERON PHARMACEUTICAL -3.5%
4/27 Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival -3.5%
4/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. They now have a $575.00 price target on the stock, up previously from $540.00. -3.3%
3/10 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: GOLDSTEIN JOSEPH L -3.3%
2/27 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock. -8.6%
3/11 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: YANCOPOULOS GEORGE -7.1%
5/7 Q1/2019 3/31/2019 EPS 4.450 ZacksConsensus 5.240 ActVsEst (0.790) - Miss -6.6%
4/20 Form 4 REGENERON PHARMACEUTICAL For: Apr 16 Filed by: LAROSA JOSEPH J -5.1%
8/14 Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol -4.1%
5/9 Form CT ORDER REGENERON PHARMACEUTICAL -3.5%
4/27 Phase 3 Trial of Libtayo® (cemiplimab) as Monotherapy for First-Line Advanced Non-small Cell Lung Cancer Stopped Early Due to Highly Significant Improvement in Overall Survival -3.5%
4/28 Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was downgraded by analysts at Citigroup Inc from a "buy" rating to a "neutral" rating. They now have a $575.00 price target on the stock, up previously from $540.00. -3.3%
3/10 Form 4 REGENERON PHARMACEUTICAL For: Mar 09 Filed by: GOLDSTEIN JOSEPH L -3.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: